Department of Orthopedic Surgery, Mayo Clinic, Jacksonville, FL, USA.
Division of Transplant Medicine, Mayo Clinic, Jacksonville, FL, USA.
Cartilage. 2019 Oct;10(4):432-443. doi: 10.1177/1947603518796142. Epub 2018 Aug 30.
Bone marrow aspiration and concentration (BMAC) is becoming a more common regenerative therapy for musculoskeletal pathology. In our current pilot study, we studied patients with mild-to-moderate bilateral knee osteoarthritis, compared pain at 12-month follow-up between BMAC-injected and saline-injected knees, and examined cartilage appearance measured by magnetic resonance imaging (MRI) T2 quantitative mapping.
Twenty-five patients with mild-to-moderate bilateral osteoarthritic knee pain were randomized to receive BMAC into one knee and saline placebo into the other. Bone marrow was aspirated from the iliac crests, concentrated in an automated centrifuge, combined with platelet-poor plasma for knee injection, and compared with saline injection into the contralateral knee. Primary outcome measures were T2 MRI cartilage mapping at 6-month and Visual Analog Scale and Osteoarthritis Research Society International Intermittent and Constant Osteoarthritis Pain scores and radiographs at 12-month follow-up.
Constant, intermittent, and overall knee pain remained significantly decreased from baseline at 12-month follow-up (all ⩽ 0.01), with no apparent difference between BMAC- and saline-treated knees (all ⩾ 0.54). A similar significant increase from baseline to 12-month follow-up regarding quality of life was observed for both BMAC- and saline-treated knees (all ⩽ 0.04). T2 quantitative MRI mapping showed no significant changes as a result of treatment.
BMAC is safe to perform and relieves pain from knee arthritis but showed no superiority to saline injection at 12-month follow-up. MRI cartilage sequences failed to show regenerative benefit with single BMAC injection. The mechanisms of action that led to pain relief remain unclear and warrant further studies.
骨髓抽吸和浓缩(BMAC)正成为治疗肌肉骨骼病理学的一种更为常见的再生疗法。在我们目前的初步研究中,我们研究了患有轻度至中度双侧膝关节骨关节炎的患者,比较了 12 个月随访时 BMAC 注射膝关节和生理盐水注射膝关节的疼痛,并检查了磁共振成像(MRI)T2 定量图谱测量的软骨外观。
25 例轻度至中度双侧膝关节骨关节炎疼痛患者随机分为接受 BMAC 注射一侧膝关节和生理盐水安慰剂注射另一侧膝关节。从髂嵴抽吸骨髓,在自动离心机中浓缩,与血小板减少的血浆混合用于膝关节注射,并与对侧膝关节的生理盐水注射进行比较。主要观察指标是 6 个月时 T2 MRI 软骨图谱和视觉模拟量表(VAS)以及骨关节炎研究协会国际间歇性和持续性骨关节炎疼痛评分和 12 个月时的 X 线片。
持续性、间歇性和整体膝关节疼痛在 12 个月随访时均较基线显著降低(均 ⩽ 0.01),BMAC 和生理盐水治疗膝关节之间无明显差异(均 ⩾ 0.54)。BMAC 和生理盐水治疗膝关节的生活质量均从基线显著增加到 12 个月随访时(均 ⩽ 0.04)。T2 定量 MRI 图谱显示治疗后无明显变化。
BMAC 安全可行,可缓解膝关节关节炎疼痛,但在 12 个月随访时与生理盐水注射相比无优势。单次 BMAC 注射的 MRI 软骨序列未显示出再生益处。导致疼痛缓解的作用机制尚不清楚,需要进一步研究。